ROLE OF PET/CT IN THE EVALUATION OF PRIMARY MALIGNANT LYMPHOMA OF THE CERVIX AND UTERUS

2016 ◽  
Author(s):  
Isao Otsuka
Keyword(s):  
Malignant Lymphoma ◽  
Pet Ct

Role of PET/CT screening in detecting a second primary carcinoma in patients with malignant lymphoma

2011 ◽  
Vol 90 (12) ◽  
pp. 1485-1486 ◽  
Author(s):  
Reona Sakemura ◽  
Junji Hiraga ◽  
Takahito Okuda ◽  
Shinichi Mizuno
Keyword(s):  
Malignant Lymphoma ◽  
Primary Carcinoma ◽  
Second Primary ◽  
Ct Screening ◽  
Pet Ct

Clinical Role of FDG PET/CT for Methotrexate-Related Malignant Lymphoma

2011 ◽  
Vol 36 (7) ◽  
pp. 533-537 ◽  
Author(s):  
Ryogo Minamimoto ◽  
Kimiteru Ito ◽  
Kazuo Kubota ◽  
Miyako Morooka ◽  
Yoko Masuda-Miyata ◽  
...  
Keyword(s):  
Malignant Lymphoma ◽  
Fdg Pet ◽  
Clinical Role ◽  
Pet Ct ◽  
Fdg Pet Ct

PET/CT IN THE DIAGNOSIS OF PANCREATIC CANCER: LITERATURE REVIEW

2018 ◽  
pp. 57-67
Author(s):  
P. E. Tulin ◽  
M. B. Dolgushin ◽  
D. I. Nevzorov ◽  
P. V. Kochergin ◽  
Yu. I. Patyutko
Keyword(s):  
Pancreatic Cancer ◽  
Literature Review ◽  
Pancreatic Neoplasms ◽  
Poor Prognosis ◽  
Modern Imaging ◽  
Pet Ct

Pancreatic cancer has a poor prognosis, often because most pancreatic neoplasms are found to be unresectable at diagnosis. Early staging of the tumor process can change the tactics of treatment and affect the survival of patients. The purpose of this review is to provide an overview of pancreatic cancer and the role of modern imaging in its diagnosis with an emphasis on PET/CT with a various radiopharmaceuticals.

Hybrid Imaging in Evaluation of Abdominal Sarcoidosis

2018 ◽  
Vol 15 (1) ◽  
pp. 26-31 ◽  
Author(s):  
Isidora Grozdic Milojevic ◽  
Dragana Sobic-Saranovic ◽  
Nebojsa Petrovic ◽  
Slobodanka Beatovic ◽  
Marijana Tadic ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Therapy Response ◽  
Ct Examination ◽  
Abdominal Disease ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Total Remission ◽  
Active Disease

Objective: To determine the prevalence of abdominal involvement, distribution pattern and evaluate role of hybrid molecular imaging in patients with abdominal sarcoidosis. Methods: Between January 2010 and December 2011, 98 patients with chronic sarcoidosis and presence of prolonged symptoms or other findings suggestive of active disease were referred to FDG PET/CT examination. Active disease was found in 82 patients, and they all were screened for the presence of abdominal sarcoidosis on FDG PET/CT. All patients also underwent MDCT and assessment of serum ACE level. Follow up FDG PET/CT examination was done 12.3±5.4 months after the baseline. Results: Abdominal sarcoidosis was present in 31/82 patients with active sarcoidosis. FDG uptake was present in: retroperitoneal lymph nodes (77%), liver (26%), spleen (23%), adrenal gland (3%). Majority of patients had more than two locations of disease. Usually thoracic disease was spread into the extrathoracic localizations, while isolated abdominal sarcoidosis was present in 10% of patients. After first FDG PET/CT examination therapy was changed in all patients. Eleven patients came to the follow up examination where SUVmax significantly decreased in the majority of them. Three patients had total remission, three had absence of abdominal disease but discrete findings in thorax and others had less spread disease. ACE levels did not correlate with SUVmax level. Conclusion: FDG PET/CT can be a useful tool for detection of abdominal sarcoidosis and in the evaluation of therapy response in these patients. Awareness of the presence of intra-abdominal sarcoidosis is important in order to prevent long-standing unrecognized disease.

The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art

2020 ◽  
Vol 13 (1) ◽  
pp. 24-31 ◽  
Author(s):  
Angelo Castello ◽  
Egesta Lopci
Keyword(s):  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Evaluation Criteria ◽  
Advanced Melanoma ◽  
Response Criteria ◽  
Response Evaluation ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Background: Immune checkpoint inhibitors (ICI) have achieved astonishing results and improved overall survival (OS) in several types of malignancies, including advanced melanoma. However, due to a peculiar type of anti-cancer activity provided by these drugs, the response patterns during ICI treatment are completely different from that with “old” chemotherapeutic agents. Objective: To provide an overview of the available literature and potentials of 18F-FDG PET/CT in advanced melanoma during the course of therapy with ICI in the context of treatment response evaluation. Methods: Morphologic criteria, expressed by Response Evaluation Criteria in Solid Tumors (RECIST), immune-related response criteria (irRC), irRECIST, and, more recently, immune-RECIST (iRECIST), along with response criteria based on the metabolic parameters with 18F-Fluorodeoxyglucose (18FFDG), have been explored. Results: To overcome the limits of traditional response criteria, new metabolic response criteria have been introduced on time and are being continuously updated, such as the PET/CT Criteria for the early prediction of Response to Immune checkpoint inhibitor Therapy (PECRIT), the PET Response Evaluation Criteria for Immunotherapy (PERCIMT), and “immunotherapy-modified” PET Response Criteria in Solid Tumors (imPERCIST). The introduction of new PET radiotracers, based on monoclonal antibodies combined with radioactive elements (“immune-PET”), are of great interest. Conclusion: Although the role of 18F-FDG PET/CT in malignant melanoma has been widely validated for detecting distant metastases and recurrences, evidences in course of ICI are still scarce and larger multicenter clinical trials are needed.

Sign in / Sign up

Export Citation Format

Share Document